Description

Xolair (Omalizumab) – Uses, Dosage, Side Effects & Storage Guide

Xolair (Omalizumab) is a prescription monoclonal antibody used to treat moderate to severe allergic asthma, chronic spontaneous urticaria (CSU or hives), and nasal polyps in patients aged 12 years and older. It works by targeting Immunoglobulin E (IgE), a key antibody responsible for allergic reactions, helping to reduce symptoms and improve quality of life.

---

• 

What is Xolair Used For?

✅ Allergic Asthma – Add-on therapy for patients whose asthma is not controlled with inhaled corticosteroids and long-acting beta2-agonists.
✅ Chronic Spontaneous Urticaria (Hives) – For patients who do not respond adequately to standard antihistamines.
✅ Nasal Polyps – Helps reduce inflammation and shrink nasal polyps in adults with chronic rhinosinusitis.

---

How Does Xolair Work?

• Blocks IgE activity: Omalizumab binds to free IgE in the blood.

• Prevents allergic response: Stops IgE from attaching to mast cells and basophils.

• Reduces inflammation: Inhibits the release of histamine and inflammatory mediators.

• Improves symptoms: Leads to fewer asthma attacks, less itching, reduced hives, and smaller nasal polyps.

---

Xolair Dosage & Administration

Dosage depends on the condition, patient weight, and baseline IgE levels.

• Allergic Asthma: 75 mg – 375 mg every 2 to 4 weeks.

• Chronic Spontaneous Urticaria: 150 mg or 300 mg every 4 weeks.

• Nasal Polyps: 75 mg – 600 mg every 2 or 4 weeks.

• Children (6–11 years): Dosing based on weight and IgE levels.

Method of Use:

• Administered as a subcutaneous injection.

• If the dose is higher than 150 mg, it must be divided across multiple injection sites.

• First doses are usually given in a clinic with monitoring due to risk of severe allergic reaction (anaphylaxis).

---

Effectiveness of Xolair

• Asthma Control: Reduces asthma attacks and improves breathing in patients with severe allergic asthma.

• Chronic Hives: Clinical studies show itch severity reduced by 48% (150 mg) and 67% (300 mg) after 12 weeks.

• Nasal Polyps: Helps shrink polyps and reduce nasal congestion.

• Reduced Medication Use: Many patients can lower their use of corticosteroids while maintaining asthma control.

---

Side Effects of Xolair

Common side effects include:

• Injection site reactions (pain, redness, swelling)

• Headache

• Upper respiratory infections

Serious but rare side effects:

• Anaphylaxis (life-threatening allergic reaction) – may occur after any dose.

• Increased risk of parasitic infections in certain regions.

• Possible link to cancer development or worsening of existing cancers.

---

Safety Precautions

• Xolair is not for sudden asthma attacks – use a rescue inhaler as prescribed.

• Patients must be monitored for at least 2 hours after each injection during initial treatment.

• Discuss use during pregnancy or breastfeeding with your doctor.

• Patients with latex allergy should avoid the prefilled syringe version, as the needle cap contains natural rubber.

• Do not suddenly stop oral steroids when starting Xolair; tapering should be supervised by a doctor.

---

Drug Interactions

• No significant drug interactions reported so far.

• May affect blood test results for IgE (levels remain elevated for up to 1 year after stopping treatment).

• Can be safely used with:

  • Inhaled corticosteroids for asthma

  • Antihistamines or topical corticosteroids for hives

  • Nasal sprays and leukotriene modifiers for nasal polyps

---

Storage Instructions

• Refrigeration: Store at 2°C – 8°C (36°F – 46°F).

• Do not freeze – discard if frozen.

• Room temperature: Can be kept up to 25°C (77°F) for 14 days; once left out, do not return to fridge.

• Keep in original carton to protect from light.

• Check expiration date before use.

• Keep away from children.

---

Patient Experience & Reviews

Most patients report:

• Significant improvement in asthma control

• Reduction in hives and itching

• Better quality of life with fewer allergic flare-ups

Overall, Xolair is considered highly effective for conditions that do not respond to standard treatments